CNS Biomarker Atlas

CNS Biomarker Atlas: blood biomarkers for brain diseases

An interactive guide to the blood biomarkers used in neurodegenerative disease research and CNS clinical trials: which brain cells they come from, which diseases they track, and when measuring them inside brain-derived extracellular vesicles (EVs) adds signal that whole plasma misses.

From brain to blood

Pick a brain cell type to see the biomarkers it releases.

Line drawing of the human brain with four brain cell types marked
Released by

Astrocytes

Support cells that react early to injury and amyloid. Their markers read out reactive gliosis.

Released by

Oligodendrocytes

The myelin-forming cells, and the site of α-synuclein inclusions in multiple system atrophy.

α-synuclein (oligodendroglial)Separating multiple system atrophy from Parkinson’s disease
Myelin proteinsDemyelination and white-matter injury (under review)
Released by

Microglia

The brain’s immune cells, and a window on neuroinflammation.

sTREM2Microglial activation (under review)

How a brain signal reaches the blood tube

  1. 01Brain cells release vesiclesEach carries proteins and RNA from its cell of origin.
  2. 02Vesicles reach the bloodstreamThere they mix with vesicles from the rest of the body.
  3. 03500 µL of plasma or serumEDTA plasma or serum from a routine blood draw.
  4. 04ExoSORT™ isolationProprietary antibodies against neuronal and oligodendroglial surface proteins capture brain-derived vesicles.
  5. 05The cargo is measuredBiomarkers are read from inside the brain’s own vesicles. How ExoSORT™ works

Disease × biomarker map

Switch between whole plasma and brain-derived EVs to see where reading the brain’s own vesicles adds signal. Hover over a cell to compare both sample types.

Measured in
Blood biomarker evidence by disease
DiseaseNfLGFAPp-Tau217Aβ42/40α-synucleinTDP-43UCH-L1
Alzheimer’s disease
Parkinson’s disease
Lewy body dementia
Multiple system atrophy
PSP / CBD
ALS
Frontotemporal dementia
Huntington’s disease
Multiple sclerosis
Traumatic brain injury
Stroke
StrongModerateEmergingLimitedRatings reflect the strength of published evidence for each marker as a blood biomarker in that disease.

Biomarkers in the atlas

Each marker links to a deeper guide: what it measures, which trials use it, and how NeuroDex runs it.

Neurofilament light (NfL)

A structural protein of axons released when neurons are damaged. The most widely used marker of neurodegeneration rate across diseases.

GFAP

An astrocyte protein that rises with reactive gliosis, early in Alzheimer’s disease and after traumatic brain injury.

p-Tau217

A phosphorylated form of tau that tracks Alzheimer’s pathology closely in blood.

Aβ42/40 ratio

The ratio of two amyloid-beta forms; a lower ratio reflects amyloid build-up in the brain.

α-synuclein

The protein that aggregates in Parkinson’s disease, Lewy body dementia and MSA. Also abundant in blood cells, which is why brain-derived EVs matter.

TDP-43

The protein that mislocalises in most ALS and about half of FTD cases. Expressed throughout the body, so brain-derived EVs help isolate the brain signal.

UCH-L1

A neuronal enzyme released after acute brain injury, used together with GFAP in traumatic brain injury.

Akt / mTOR pathway

Signalling proteins measured in brain-derived EVs to show a drug reached its target in the brain.

Biomarker Finder

Which biomarkers fit your trial?

Choose an indication, a phase and what you need to show. Get a suggested starting panel in under a minute.

Open the Biomarker Finder

Frequently asked questions

What is a CNS blood biomarker?

A protein or other molecule measured in blood that reflects what is happening in the brain or spinal cord, such as nerve-cell injury (NfL), astrocyte activation (GFAP) or disease pathology (p-Tau217, α-synuclein, TDP-43).

Why measure biomarkers inside brain-derived extracellular vesicles?

Many CNS proteins, including α-synuclein and TDP-43, are also made outside the brain. Isolating vesicles released by brain cells ties the measurement to the brain instead of to blood cells or other tissues.

Which blood biomarkers are used in Alzheimer’s disease trials?

p-Tau217 and the Aβ42/40 ratio for amyloid and tau pathology, GFAP for astrocyte activation, and NfL for neurodegeneration.

What sample does NeuroDex need?

A minimum of 500 µL of EDTA plasma or serum per timepoint, shipped frozen on dry ice. Results are typically ready 2–3 weeks after the samples arrive, depending on study size.

Next step

Request a sample-feasibility review

Tell us your indication, sample type and volume. Our scientists confirm which markers your samples can support.